Admedus launches ADAPT technology in India

Latest News

Admedus (ASX:AHZ) has partnered with Syncronei Medical India, with the support of the Australian Trade and Investment Commission (Austrade), to introduce ADAPT technology in India.

Physicians in India now have access to engineered tissue ADAPT as well as Admedus’ flagship product CardioCel.

CardioCel is a bio-scaffold for the management of congenital and adult structural heart abnormalities.

“In a country with approximately 50 million cardiac patients and 280,000 babies born annually with a Congenital Heart Defect (CHD), the introduction of our disruptive ADAPT technology is a significant opportunity for India’s physicians to provide life-changing outcomes for their patients,” said Admedus CEO Wayne Paterson.

“CardioCel has been available in North America and Europe for some time but this is the first time Indian physicians and patients have had access to Admedus’ world-class ADAPT technology,” he said.

ADAPT is primarily used in restorative structural heart repair and reconstruction. Treated tissue provides resistance to calcification, delivering repair with long-term durability that enables native cells to successfully grow and differentiate through the entire repair, without calcification or toxicity, said the company.

“Our clinically superior ADAPT products, invented and manufactured in our state-of-the-art manufacturing facility in Australia, are the only ones to have achieved nine years without calcification or degradation, providing Indian surgeons with a potential lifetime solution for their patients,” said Mr Paterson.

ADAPT inventor and Admedus Vice President of Cardiovascular Technologies, Professor Leon Neethling, will deliver a comprehensive series of meetings and presentations with physicians in major health centres across India to demonstrate the product’s clinical applications and benefits.

The official launch activities follow the announcement in November last year that Admedus had received regulatory approval to launch CardioCel in India, with Syncronei Medical India appointed as exclusive commercial partner managing all sales, marketing and distribution.